Clinical Trials Logo

Advanced Melanoma clinical trials

View clinical trials related to Advanced Melanoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02663258 Withdrawn - Advanced Melanoma Clinical Trials

A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)

ADAPTeM
Start date: January 2016
Phase: Phase 2
Study type: Interventional

Abbreviated Title: An explorative Phase II study of Anti-PD-1 (Pembrolizumab) in patients with advanced melanoma (ADAPTeM) Trial Phase: Phase II Clinical Indication: Stage III unresectable/stage IV metastatic melanoma Trial Type: Exploratory Phase II trial Route of administration: Intravenous Pembrolizumab, 200mg, 3weekly Trial Blinding: Unblinded; open label Phase II study Treatment Groups: All participants treated with Pembrolizumab, 200mg iv, 3weekly Number of trial subjects: 40 Estimated duration of trial: 24 months Duration of Participation: 24 months